Search results for: “astrazeneca”
-
AstraZeneca signs definitive agreement to acquire Alexion Pharmaceuticals
•
CAMBRIDGE: AstraZeneca and Alexion Pharmaceuticals Inc. have entered into a definitive agreement for AstraZeneca to acquire Alexion, a…
-
AstraZeneca sells Crestor to Grünenthal in Europe in a $320 million deal
•
LONDON: AstraZeneca has agreed to sell the rights to Crestor (rosuvastatin) and associated medicines in over 30 countries…
-
AstraZeneca selects ImpediMed’s SOZO devices for upcoming clinical trials
•
BRISBANE: ImpediMed Limited announced a second contract valued at over $2.0 million for its SOZO Digital Health Platform…
-
AstraZeneca’s Forxiga approved in the EU for heart failure
•
LONDON, UK: AstraZeneca‘s Forxiga (dapagliflozin) has been approved in the European Union (EU) for the treatment of symptomatic…
-
Lonza signs agreement to manufacture AstraZeneca’s COVID-19 treatment
•
BASEL: Lonza has signed an agreement with AstraZeneca to manufacture AZD7442, a combination of two long-acting antibodies (LAABs)…
-
AstraZeneca agrees to sell commercial rights to Atacand to Cheplapharm Arzneimittel GmbH
•
LONDON: AstraZeneca has agreed to sell the commercial rights to Atacand (candesartan cilexetil) and Atacand Plus (a fixed-dose…
-
AstraZeneca’s COVID-19 long-acting antibody combination advances into Phase III clinical trials
•
LONDON: AstraZeneca’s long-acting antibody (LAAB) combination, AZD7442, will advance into two Phase III clinical trials in more than…
-
AstraZeneca’s Farxiga granted breakthrough therapy designation in US for chronic kidney disease
•
LONDON: AstraZeneca’s Farxiga (dapagliflozin) has been granted Breakthrough Therapy Designation (BTD) in the US for patients with chronic…
-
AstraZeneca to list US ADR equity and all US debt securities on Nasdaq
•
LONDON: AstraZeneca today announced that it will be transferring the listing of its American Depositary Receipts (ADRs) and…
-
Oxford Biomedica signs Supply Agreement with AstraZeneca to expand manufacturing support of COVID-19 vaccine
•
OXFORD: Oxford Biomedica plc, a leading gene and cell therapy group, has signed an 18 month supply agreement…
-
AstraZeneca’s Imfinzi approved in EU for treatment of extensive-stage small cell lung cancer
•
LONDON: AstraZeneca’s Imfinzi (durvalumab) has been approved in the European Union for the 1st-line treatment of adults with…
Stay Informed with the Latest News and Updates
- Contact Us
- London Stock Exchange
- Singapore Exchange
- Canadian Exchange
- Australian Exchange
- Oslo Bourse
- PSX
- Ratings
- Euronext
- MENA
- Nasdaq Nordic
- Wire
- Business & Finance
- Gadget Reviews
- About Us: A Comprehensive Financial News Database
All news and articles on NewsnReleases are based on press releases, corporate announcements and analysts’ reports issued to London Stock Exchange (LSE), Euronext, Singapore Exchange (SGX), Japan Stock Exchange (JPX), Dubai Financial Market (DFM), Saudi Stock Exchange (Tadawul), Qatar Stock Exchange (QSE), BSEIndia, Australia Stock Exchange etc.